10mg tirzepatide to semaglutide conversion Dose Guide Switching between weight-loss medications -

This blog is an extension of our poster presented at ISPOR 2024, titled Baseline A1C and BMI trends for people with type 2 diabetes receiving first-time GLP-1 RA prescriptions

GLP-1 medications are not FDA-approved for PMOS but show promising off-label evidence

Contact us to schedule a consultation and discuss how tirzepatide injections may fit into your personalized weight management plan

Skeletal muscle mass is not muscle quality

Lower incidence of side effects and improved tolerability In clinical trials, 78.9% to 81.8% of patients using tirzepatide experienced side effects compared to 72% of participants in the placebo group